Financial Performance - The proposed profit distribution plan for 2020 includes a cash dividend of RMB 4 per 10 shares, totaling RMB 32,659,200, which accounts for 47.20% of the net profit attributable to shareholders[6]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 15% year-over-year growth[16]. - In 2020, the company's operating revenue decreased by 3.12% year-on-year to CNY 222,398,393.41, primarily due to the impact of the COVID-19 pandemic on routine testing volumes in domestic medical institutions[26]. - The net profit attributable to shareholders decreased by 2.61% year-on-year to CNY 69,188,424.17, influenced by a donation of CNY 4,978,500 to support medical institutions during the pandemic[26]. - The company reported a total revenue of 82,811,600.00 RMB, with a net profit of 12,972,626.60 RMB, indicating a significant growth in financial performance compared to the previous year[70]. - The company achieved operating revenue of RMB 222.40 million, a year-on-year decrease of 3.12%, and a net profit attributable to shareholders of RMB 69.19 million, a decrease of 2.61%[84]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion for the fiscal year, representing a 20% year-over-year growth[155]. - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming for $1.875 billion[155]. Risk Management - The company has detailed various operational risks and corresponding countermeasures in the report, emphasizing the importance of risk management[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans and strategies do not constitute a substantive commitment to investors[7]. - The company faces risks related to potential technological changes in the thrombosis and hemostasis diagnostics market, which could impact existing products[89]. - The company may experience adverse effects on its operating performance if regional distributors fail to meet sales targets or if cooperation is disrupted[97]. - The company is exposed to foreign exchange risks due to sales and procurement in foreign currencies, which may impact operating performance[99]. - The company faces risks due to a single product structure and limited product registration certificates, which may not meet future market demands[96]. Governance and Compliance - The audit report issued by the accounting firm is a standard unqualified opinion, ensuring the accuracy of the financial statements[5]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[9]. - The company has not faced any situations where more than half of the directors could not guarantee the authenticity of the annual report[11]. - The company has a comprehensive governance structure in place, ensuring accountability and transparency in its operations[9]. - The company is committed to maintaining the integrity and completeness of its financial reporting, as stated by the management team[6]. - The company has established a structured profit distribution system in place, including specific arrangements for cash dividends[145]. - The company will prioritize transparency and fairness in all related party transactions to safeguard shareholder interests[158]. Research and Development - The R&D expenditure accounted for 6.01% of operating revenue, slightly down from 6.04% in 2019[25]. - The company has established a core technology cluster in the field of thrombus and hemostasis in vitro diagnostics, covering five major technology categories[36]. - The company has developed 15 core technologies, including blood rheology measurement and coagulation diagnostic testing platforms, and holds 26 patents, of which 5 are invention patents[43]. - The company is focusing on the development of new technologies that improve the sensitivity and speed of plasma viscosity detection, which is crucial for clinical applications[48]. - The company is actively pursuing the commercialization of its D-dimer and FDP antibody products, which are expected to replace imported materials upon successful development[50]. - The company has a robust pipeline of research projects focused on thrombus and hemostasis diagnostics, leveraging its core technology platforms to expand its product line[76]. - The company plans to invest raised funds in production base construction and R&D center development to mitigate dilution of immediate returns[177]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next two years[16]. - A strategic acquisition of a smaller biotech firm was completed, enhancing the company's R&D capabilities and expected to contribute an additional 150 million RMB in revenue by the end of 2021[16]. - The company is focusing on the development of high-performance fully automated coagulation testing instruments and specialized reagents to meet market trends[86]. - The company has established a nationwide marketing service network covering 29 provinces and key cities, excluding Tibet, Qinghai, and Hong Kong and Macau[79]. - The company has developed a competitive advantage in the domestic market by providing high-cost performance testing systems, successfully replacing imported products in secondary hospitals and below[78]. Shareholder Commitments - The controlling shareholder has committed to not transferring shares for 36 months post-IPO[148]. - The commitments outlined will remain effective throughout the company's listing period and until the controlling shareholder is no longer associated with the company[158]. - The controlling shareholder will notify the company of any competitive opportunities that may arise, ensuring they are offered to the company first[157]. - The company will adhere to all relevant regulations and internal rules regarding related party transactions to maintain compliance and protect shareholder rights[158]. - The company has a three-year shareholder dividend return plan post-IPO, which will be strictly followed[182]. Financial Position - The company's total assets at the end of 2020 reached CNY 1,401,464,960.27, an increase of 228.45% compared to the beginning of the year[26]. - The net assets attributable to shareholders increased by 261.94% year-on-year to CNY 1,356,152,023.97, bolstered by net proceeds of CNY 92,426,960 from the IPO[26]. - The company's total net profit attributable to shareholders for 2020 was RMB 69,188,424.17[146]. - The company’s cash dividend distribution plan is subject to approval at the annual general meeting[145]. Operational Efficiency - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management and pricing strategies[16]. - The company is investing 100 million RMB in new technology to improve production efficiency, aiming for a 30% reduction in operational costs[16]. - The company plans to implement cost-cutting measures aimed at reducing operational expenses by 5% over the next year[151]. - The company is focused on optimizing product structure and expanding overall scale to ensure sustainable development[178].

Financial Performance - Operating revenue for the year-to-date was ¥50,843,046.14, representing a 58.45% increase year-on-year[6]. - Net profit attributable to shareholders was ¥19,451,138.70, a significant increase of 451.46% compared to the same period last year[6]. - Basic and diluted earnings per share were both ¥0.24, reflecting a 300% increase year-on-year[6]. - The net profit after deducting non-recurring gains and losses was ¥19,344,242.74, an increase of 196.98% year-on-year[6]. - The company reported a total comprehensive income of ¥19,451,138.70 for Q1 2021, compared to ¥3,527,198.52 in Q1 2020, highlighting strong financial performance[34]. - The net profit for Q1 2021 reached ¥19,725,881.11, a significant increase from ¥3,352,107.92 in Q1 2020, marking a growth of approximately 487%[35]. - The operating profit for Q1 2021 was ¥22,937,581.80, compared to ¥7,562,842.98 in Q1 2020, indicating a year-over-year increase of about 203%[35]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,420,928,668.29, an increase of 1.39% compared to the end of the previous year[6]. - The company’s total liabilities decreased by 58.74% in accounts receivable financing, down to ¥502,137.90, mainly due to the maturity of bank acceptance bills[14]. - Total liabilities were ¥45,325,505.62, showing a slight increase from ¥45,312,936.30 at the end of 2020[25]. - The total current assets decreased by 153,701.84 RMB, totaling 1,327,774,197.54 RMB[44]. - The company reported a total equity of 1,356,152,023.97 RMB, unchanged from the previous year[46]. - Total liabilities reached $94,243,107.00, reflecting a decrease of $6,085,906.30[50]. Cash Flow - Net cash flow from operating activities was ¥5,615,737.00, a recovery from a negative cash flow of ¥10,916,233.02 in the previous year[6]. - The company reported a net cash flow from operating activities of ¥5,615,737.00 in Q1 2021, a turnaround from a negative cash flow of ¥10,916,233.02 in Q1 2020[39]. - The cash inflow from operating activities totaled ¥63,950,201.16 in Q1 2021, compared to ¥39,378,594.13 in Q1 2020, showing improved operational efficiency[39]. - The net cash flow from financing activities was -424,528.30 RMB, indicating a cash outflow[43]. Shareholder Information - The total number of shareholders at the end of the reporting period was 8,753[11]. - The largest shareholder, Wu Shiming, holds 34.66% of the shares, totaling 28,298,431 shares[11]. Expenses - The cost of goods sold increased by 45.12%, amounting to ¥19,507,128.16, driven by the rise in operating revenue[15]. - Research and development expenses increased by 38.71% to ¥4,124,300.79, reflecting higher personnel costs and product registration fees[15]. - The company reported a 394.33% increase in income tax expenses, totaling ¥3,212,740.98, due to higher operating profits[16]. - The company’s management expenses rose by 35.10% to ¥3,019,415.55, driven by an increase in personnel and intermediary fees[16]. - The company incurred financial expenses of -¥7,344,804.98 in Q1 2021, compared to -¥2,321,449.34 in Q1 2020, indicating a change in financial strategy[35]. Government Subsidies - The company received government subsidies amounting to ¥125,909.09, which are closely related to its normal business operations[10]. Accounting Changes - The company adopted a new leasing standard starting January 1, 2021, resulting in an increase of right-of-use assets by 6,239,608.14 RMB and lease liabilities by 6,085,906.30 RMB[47]. - The company adopted the revised Accounting Standards for Leases starting January 1, 2021, resulting in an increase of $6,239,608.14 in right-of-use assets[51].

Financial Performance - Operating revenue for the first nine months decreased by 4.77% year-on-year, totaling CNY 151,135,602.87[7] - Net profit attributable to shareholders decreased by 16.05% year-on-year, amounting to CNY 40,158,932.04[7] - Basic earnings per share decreased by 29.63% to CNY 0.57[8] - The net profit attributable to shareholders decreased by 16.05%, primarily due to a reduction in routine testing volumes in domestic medical institutions caused by the COVID-19 pandemic, leading to a 4.77% decline in operating revenue[22] - The net profit for Q3 2020 was CNY 15,112,444.36, down from CNY 17,447,605.30 in Q3 2019, indicating a decrease of about 13.4%[42] - The total profit for Q3 2020 was CNY 17,823,480.99, slightly lower than CNY 20,028,438.23 in Q3 2019, showing a decline of about 10.9%[42] - The company's basic earnings per share for Q3 2020 were CNY 0.21, down from CNY 0.29 in Q3 2019, a decrease of approximately 27.6%[43] - The total comprehensive income for Q3 2020 was CNY 15,112,444.36, down from CNY 17,447,605.30 in Q3 2019, indicating a decline of approximately 13.4%[43] Assets and Liabilities - Total assets increased by 219.98% year-on-year, reaching CNY 1,365,319,400.68 at the end of the reporting period[7] - Total liabilities reached CNY 38,196,868.84, down from CNY 51,997,723.42 year-over-year[38] - Total equity attributable to shareholders increased to CNY 1,327,122,531.84 from CNY 374,693,962.58, reflecting strong growth in retained earnings[34] - The company's total liabilities decreased by approximately 26.5% year-over-year, indicating improved financial health[38] - The company’s total liabilities were reported at ¥51,997,723.42, remaining consistent with the previous year, which reflects effective liability management[52] Cash Flow - The net cash flow from operating activities for the first nine months was CNY 29,456,685.13, a decrease of 1.96% year-on-year[7] - The net cash flow from operating activities decreased primarily due to the reduction in operating revenue[21] - The net cash flow from investing activities showed a significant decline of 581.72%, from -CNY 4,556,016.32 in 2019 to -CNY 31,059,154.12 in 2020[23] - The net cash flow from financing activities increased by 748.95%, rising from CNY 107,500,363.98 in 2019 to CNY 912,623,588.23 in 2020[23] - Cash flow from operating activities for the first nine months of 2020 was CNY 191,503,072.86, up from CNY 181,312,285.32 in the first nine months of 2019, reflecting a growth of approximately 5.67%[46] - The net cash flow from financing activities in Q3 2020 was CNY 912,623,588.23, significantly higher than CNY 107,500,363.98 in Q3 2019, showing an increase of about 748.57%[47] Shareholder Information - The company had a total of 10,752 shareholders at the end of the reporting period[12] - The largest shareholder, Wu Shiming, holds 34.66% of the shares, totaling 28,298,431 shares[12] Research and Development - Research and development expenses accounted for 6.75% of operating revenue, an increase of 0.50 percentage points compared to the previous year[8] - Research and development expenses increased by 2.81% to approximately ¥10.20 million, reflecting ongoing investment in new technologies[18] - Research and development expenses for Q3 2020 were CNY 3,403,955.33, compared to CNY 3,238,793.55 in Q3 2019, reflecting an increase of approximately 5.1%[44] Government Subsidies and Other Income - The company reported a government subsidy of CNY 1,336,817.32 related to its normal business operations[9] - Other income increased by 100.62%, primarily due to an increase in government subsidies related to income[24] Market Outlook - The company anticipates a gradual recovery in testing volumes as the domestic COVID-19 situation stabilizes, although year-to-date testing volumes remain lower than the previous year[14] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[39] Equity and Capital - The company completed a public offering of 20.41 million shares in July 2020, raising a net amount of approximately ¥924.27 million, significantly increasing its cash reserves by 281.94%[15][16] - The company issued 20,412,000 shares on August 6, 2020, raising a net amount of CNY 92,426.96 million, which increased the total share capital to CNY 8164.8 million[26] Intangible Assets - The company reported a significant increase in intangible assets by 3,821.20%, primarily due to the acquisition of land use rights by its subsidiary[19] Financial Ratios - The weighted average return on equity decreased by 17.44 percentage points, primarily due to the issuance of new shares and the decline in net profit attributable to shareholders[28]

Financial Performance - The company reported a significant increase in revenue for the first half of 2020, with a total revenue of RMB 500 million, representing a 25% year-over-year growth[1]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2020, representing a 25% year-over-year growth[14]. - Operating revenue for the first half of the year was CNY 99,194,115.13, a decrease of 9.13% year-on-year[21]. - Net profit attributable to shareholders decreased by 17.59% to CNY 25,046,487.68 compared to the same period last year[21]. - Basic earnings per share decreased by 22.64% to CNY 0.41 compared to the same period last year[20]. - The company reported a total revenue of 46,030,000.00 RMB for the first half of 2020, with a net profit of 40,608,892.43 RMB, indicating a significant performance in the market[51]. - The company’s comprehensive income for the current period was CNY 25,046,487.68, reflecting a significant increase compared to the previous year's comprehensive income of CNY 71,040,074.50[129]. User Growth and Market Expansion - User data showed an increase in active users, reaching 1.2 million, which is a 30% increase compared to the previous year[1]. - User data indicates that the number of active users has reached 500,000, marking a 30% increase compared to the previous year[14]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market penetration by the end of 2021[1]. - Market expansion efforts include entering three new provinces, which are anticipated to increase market share by 15%[14]. Product Development and Innovation - New product development includes the launch of a next-generation diagnostic device, expected to increase market share by 15%[1]. - New product launches are expected to contribute an additional 200 million RMB in revenue by the end of the year[14]. - The company is investing RMB 50 million in R&D for innovative technologies in the IVD sector[1]. - The company is investing heavily in R&D, with an allocation of 150 million RMB for the development of new technologies and products[14]. - The company is focusing on expanding its product line in the thrombosis and hemostasis in vitro diagnostic field, with a rich reserve of ongoing research projects[56]. Financial Health and Management - The gross margin improved to 60%, up from 55% in the previous year, indicating better cost management[1]. - The company's R&D expenditure as a percentage of operating revenue increased by 0.73 percentage points to 6.85%[20]. - The net assets attributable to shareholders increased by 3.48% to CNY 387,740,450.26 compared to the end of the previous year[21]. - Total assets increased by 1.60% to CNY 433,522,949.52 compared to the end of the previous year[21]. - The company has maintained its business model of "independent R&D and production, sales-driven production, and distribution-focused sales" throughout the reporting period[26]. Strategic Initiatives - A strategic acquisition of a local competitor was announced, which is expected to enhance the company's product offerings and increase revenue by an estimated RMB 100 million annually[1]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a budget of 300 million RMB allocated for this purpose[14]. - A new strategic partnership has been established with a leading healthcare provider, expected to drive additional revenue of 100 million RMB annually[14]. Operational Efficiency - The company has implemented new strategies to enhance operational efficiency, aiming for a 15% reduction in operational costs by the end of 2020[1]. - Operating costs decreased by 6.04% compared to the same period last year, primarily due to a reduction in operating income[70]. - Sales expenses decreased by 10.98%, mainly due to reduced spending on meetings and travel as a result of the COVID-19 pandemic[70]. Research and Development - The company has established a core technology cluster in the field of thrombus and hemostasis in vitro diagnostics, encompassing 15 proprietary technologies[39]. - The company has developed 15 core technologies, including blood rheology measurement and coagulation diagnosis testing technology, which have received multiple national and local awards[55]. - The company has a total of 43 R&D personnel, accounting for 15.30% of the total workforce, with a total R&D compensation of 4,129,200.04 RMB and an average salary of 96,027.91 RMB[53]. Environmental and Compliance - The company reported no significant environmental penalties during the reporting period, adhering to environmental regulations and ensuring compliance in production management[84]. - The company’s solid waste management includes recycling of general industrial solid waste and proper disposal of hazardous waste, with contracts in place for waste treatment[85]. - The company’s wastewater treatment processes involve integrated facilities that ensure compliance with municipal standards, with no major environmental violations reported[86]. Challenges and Risks - The COVID-19 pandemic has increased demand for diagnostic products, although it has also led to a decline in routine medical product demand due to reduced patient visits[38]. - The company faced risks related to limited market space for blood flow detection products and reliance on a single foreign supplier for key raw materials[64][65]. - The company anticipates potential risks of declining performance in 2020 compared to 2019 if the COVID-19 pandemic continues[65]. Shareholder Information - The company issued 20.41 million A-shares on August 6, 2020, raising a net amount of approximately 924.27 million yuan, increasing total shares to 81.648 million[92]. - The total owner's equity at the end of the reporting period was CNY 387,740,450.26, up from CNY 195,653,524.10 in the previous year, indicating a growth of about 97.9%[127].